Risperdal® Stroke
(800) 889-9248
Risperdal® has been linked to 37 reports of stroke or stroke-like events such as blood clots and hemorrhages. Strokes affect individuals differently, depending on the severity of the Risperdal® stroke and the area of the brain the Risperdal® stroke involved. When a Risperdal® stroke has occurred it can means that either the blood supply to the part of the brain is suddenly interrupted or a blood vessel in the brain has burst causing blood to spill into the brain cells.
The result of suffering a Risperdal® stroke can affect the entire body, causing paralysis, cognitive effects, emotional problems, speech difficulties, loss of mobility, and other effects. The Risperdal® stroke patients daily life activities may no longer be able to be fulfilled following the stroke. Not only may the Risperdal® stroke survivor not even know how to perform a daily task due to confusion, but also paralysis or weakness that may be present could prevent the individual from even being able to fulfill them.
Risperdal® schizophrenia drug is Johnson & Johnsons second most profitable medication, responsible for $2.1 billion in annual global sales. Risperdal®s future is uncertain as reports of Risperdal® stroke and Risperdal® deaths have led J&J to announce the company will be sending out thousands of letters to physicians warning of the serious Risperdal® side effects. In addition, J&J will be changing Risperdal® labeling to better warn of the risks of Risperdal® strokes in elderly patients.
In October 2002, a Risperdal® warning letter was sent to Canadian doctors and pharmacists after reports of 37 Risperdal® stroke or stroke-like events like blood clots and hemorrhages occurred, including 16 Risperdal® deaths. The Risperdal® warning letter sent to Canadian physicians and pharmacists also noted that two clinical trials of elderly dementia patients in which elderly Risperdal® dementia patients had a higher proportion of strokes or related events than patients that had received placebo.
Risperdal® clinical trials have shown that 4% of Risperdal® patients suffered stroke or stroke-related events, opposed to just 2% of people receiving placebos. There were four Risperdal® deaths and just on death amongst placebo recipients. Many people are wondering why earlier Risperdal® warnings were not issued until the recent worrisome Risperdal® clinical trials despite the six-month previous Canadian announcement.
For more information on Risperdal® stokes please contact us to confer with a Risperdal® lawyer.
